icon-folder.gif   Conference Reports for NATAP  
 
 

16thEuro

Back grey_arrow_rt.gif
 
 
 
Dolutegravir plus lamivudine maintains HIV-1 suppression
through week 48 in a pilot randomized trial (ASPIRE)

 
 
  Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
 
1Babafemi O. Taiwo, 2Vincent Marconi, 1Baiba Berzins, 3Carlee Moser, 4Amesika N. Nyaku, 5Carl J. Fichtenbaum, 6Timothy Wilkin, 7Constance A. Benson, 8Susan L. Koletar, 2Jonathan Colasanti, 9Jonathan Li, 9Paul E. Sax, and the ASPIRE Team 1Northwestern University, Infectious Diseases, Chicago, U.S., 2Emory University, Atlanta, U.S., 3Harvard School of Public Health, Boston, U.S., 4Rutgers, Newark, U.S., 5University of Cincinnati, Cincinnati, U.S., 6Cornell University, New York, U.S., 7University of California, San Diego, U.S., 8The Ohio State University, Columbus, U.S., 9Brigham and Women's Hospital, Boston, U.S.,

1108171

1108172

1108173

1108174

1108175

1108176

1108177

1108178